Pfizer Inc (PFE)

$27.22 -0.25 (-0.91%)
Market Cap 156.20B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.39
Forward PE 9.12
Profit Margin 12.42%
Debt to Equity Ratio 0.75
Volume 27,047,500
Avg Vol 43,338,461
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 22%
Beta 0.43
Analysts Sell
Price Target $28.98

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
Micheal_Pothead
Micheal_Pothead Apr. 10 at 3:25 PM
$PFE who wants to defend it today?
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Apr. 10 at 3:19 PM
$PFE - We’re going down with Fastly and Cloudflare. We joined their section today.
0 · Reply
Pissed_of_retards2
Pissed_of_retards2 Apr. 10 at 3:06 PM
$NVAX In case R21 will be soon for adults Jacobs should maybe discuss next steps with SII or ask Sanofi or Pfizer if they will help with distribution in Asia? But i assume SII is capable this. On other side SII is only producer but SNY has market channels. $SNY $PFE
0 · Reply
_Crim_Jamer_
_Crim_Jamer_ Apr. 10 at 3:04 PM
$PFE that's more like it! $PFE is supposed to stay stuckat 27.
0 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 10 at 3:02 PM
$PFE POS as always
0 · Reply
Pissed_of_retards2
Pissed_of_retards2 Apr. 10 at 2:56 PM
$NVAX $SNY $PFE $MRK Trial Results (March 2026): The landmark SERVAL trial, which is testing R21 in all age groups (infants to adults) in The Gambia and Burkina Faso, is scheduled to conclude its final results by March 2026. WHO Policy Review (Mid-to-Late 2026): Historically, the WHO reviews trial data shortly after publication to consider expanding recommendations. If the SERVAL data is successful, a policy recommendation for adults could follow in late 2026. Market Availability (2027 onwards): General market access for adults—such as for travelers or mass adult vaccination campaigns—is likely to begin in 2027, once individual national regulators and international agencies like Gavi update their procurement guidelines.
0 · Reply
breakawayrider
breakawayrider Apr. 10 at 2:50 PM
$PFE Last 10 days or so… RBC reaffirmed sell - 28 PT WF with a hold - 25 PT BoA lowered PT 27–>26, remained neutral MS maintained hold - 28 PT All in all, price action has been pretty decent considering analyst attacks and uptrend looks to remain intact…next couple weeks will be telling if we can hold here or we’re back to the gulags.
1 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 10 at 2:18 PM
$OMER Been waiting on the eu updated adopted. I think when that news hits we're off to the races Meeting ends today and we were top of the list $MRNA $PFE $OGN https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-7-10-april-2026_en.pdf
1 · Reply
NomadiCapital
NomadiCapital Apr. 10 at 1:48 PM
$PFE Use statistics in your favor. Next week starts a new 2-week candle, but it’s the final week of the current 3-week candle. Historically, the average 3W candle range is about $2.70. That suggests next week likely stays within $26 – $29.50. My plan: • Pop to $28.75–$29.50 → Writing covered calls expiring Friday • Drop near $26 → Writing cash-secured puts expiring Friday Let the probabilities work.
1 · Reply
NomadiCapital
NomadiCapital Apr. 10 at 1:43 PM
$PFE Use statistics in your favor
0 · Reply
Latest News on PFE
Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders

Apr 9, 2026, 10:00 AM EDT - 1 day ago

Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders

Why Is Pfizer Stock Dropping Tuesday?

Apr 7, 2026, 1:54 PM EDT - 2 days ago

Why Is Pfizer Stock Dropping Tuesday?

Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

Apr 2, 2026, 11:14 AM EDT - 7 days ago

Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

NVO LLY

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

Apr 1, 2026, 11:39 AM EDT - 8 days ago

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

BNTX

Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines

Apr 1, 2026, 10:13 AM EDT - 9 days ago

Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines

Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.

Mar 30, 2026, 10:44 AM EDT - 11 days ago

Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.

GSK LLY NVO PPH

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

Mar 24, 2026, 10:00 AM EDT - 17 days ago

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive

Mar 23, 2026, 12:46 PM EDT - 17 days ago

An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive

VALN

Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive

Mar 23, 2026, 10:35 AM EDT - 18 days ago

Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive

VALN

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

Mar 23, 2026, 9:36 AM EDT - 18 days ago

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

VALN

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Mar 23, 2026, 7:07 AM EDT - 18 days ago

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

VALN

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

Mar 23, 2026, 7:02 AM EDT - 18 days ago

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

VALN

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

Mar 23, 2026, 6:47 AM EDT - 18 days ago

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

VALN

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

Mar 23, 2026, 6:45 AM EDT - 18 days ago

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

VALN

5 ‘Healthy' Dividends Paying Up To 14.1%

Mar 22, 2026, 9:45 AM EDT - 19 days ago

5 ‘Healthy' Dividends Paying Up To 14.1%

ARE BME DOC HQH

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Mar 20, 2026, 4:30 PM EDT - 20 days ago

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

Mar 19, 2026, 6:45 AM EDT - 22 days ago

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 22 days ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

Mar 17, 2026, 7:49 AM EDT - 24 days ago

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Mar 17, 2026, 6:45 AM EDT - 24 days ago

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

Mar 9, 2026, 7:27 AM EDT - 4 weeks ago

Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

Mar 9, 2026, 6:45 AM EDT - 4 weeks ago

Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

China approves Pfizer GLP-1 drug for weight management

Mar 6, 2026, 12:40 AM EST - 5 weeks ago

China approves Pfizer GLP-1 drug for weight management

Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund

Mar 5, 2026, 4:48 PM EST - 5 weeks ago

Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund

NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

Mar 4, 2026, 8:55 AM EST - 5 weeks ago

NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

SMWB

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

Mar 3, 2026, 8:10 AM EST - 5 weeks ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

PRGO XRAY

Pfizer CEO flags issues with FDA's vaccine leadership

Mar 2, 2026, 11:14 AM EST - 5 weeks ago

Pfizer CEO flags issues with FDA's vaccine leadership

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Feb 27, 2026, 10:00 AM EST - 6 weeks ago

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Feb 24, 2026, 2:29 PM EST - 6 weeks ago

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Feb 24, 2026, 7:45 AM EST - 6 weeks ago

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Pfizer in diabetes drug deal with Sciwind Biosciences

Feb 23, 2026, 10:26 PM EST - 6 weeks ago

Pfizer in diabetes drug deal with Sciwind Biosciences

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

Feb 23, 2026, 3:15 PM EST - 6 weeks ago

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

MRK MRNA

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Feb 23, 2026, 10:00 AM EST - 6 weeks ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Is There 25% Downside For Pfizer Stock?

Feb 18, 2026, 12:00 PM EST - 7 weeks ago

Is There 25% Downside For Pfizer Stock?

Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Feb 17, 2026, 6:45 AM EST - 7 weeks ago

Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Prices, pipelines and patent cliffs: Inside pharma's big reset

Feb 13, 2026, 6:13 AM EST - 2 months ago

Prices, pipelines and patent cliffs: Inside pharma's big reset

AMGN LLY NVO

These 32 favorite stocks signal the bull market is running on fumes

Feb 12, 2026, 8:05 AM EST - 2 months ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ABT ADBE AMGN AVGO BAC BK

Is Pfizer Stock Now A Value Trap?

Feb 11, 2026, 8:56 AM EST - 2 months ago

Is Pfizer Stock Now A Value Trap?

Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund

Feb 10, 2026, 3:20 PM EST - 2 months ago

Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

Feb 6, 2026, 2:55 PM EST - 2 months ago

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

Feb 6, 2026, 6:45 AM EST - 2 months ago

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

Feb 5, 2026, 7:09 PM EST - 2 months ago

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 2 months ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN GPCR LLY NVO VKTX

Silver Surges Over 15%; Pfizer Earnings Top Views

Feb 3, 2026, 12:00 PM EST - 2 months ago

Silver Surges Over 15%; Pfizer Earnings Top Views

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

Feb 3, 2026, 11:17 AM EST - 2 months ago

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

MRK

Pfizer beats quarterly estimates despite Covid product decline - reaffirms modest outlook

Feb 3, 2026, 10:15 AM EST - 2 months ago

Pfizer beats quarterly estimates despite Covid product decline - reaffirms modest outlook

Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops

Feb 3, 2026, 8:50 AM EST - 2 months ago

Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops

Pfizer maps post-Covid reset with obesity trials and deep cost cuts

Feb 3, 2026, 8:17 AM EST - 2 months ago

Pfizer maps post-Covid reset with obesity trials and deep cost cuts

Pfizer says once-a-month weight-loss drug works as it forecasts profit decline

Feb 3, 2026, 7:28 AM EST - 2 months ago

Pfizer says once-a-month weight-loss drug works as it forecasts profit decline

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

Feb 3, 2026, 7:21 AM EST - 2 months ago

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

Micheal_Pothead
Micheal_Pothead Apr. 10 at 3:25 PM
$PFE who wants to defend it today?
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Apr. 10 at 3:19 PM
$PFE - We’re going down with Fastly and Cloudflare. We joined their section today.
0 · Reply
Pissed_of_retards2
Pissed_of_retards2 Apr. 10 at 3:06 PM
$NVAX In case R21 will be soon for adults Jacobs should maybe discuss next steps with SII or ask Sanofi or Pfizer if they will help with distribution in Asia? But i assume SII is capable this. On other side SII is only producer but SNY has market channels. $SNY $PFE
0 · Reply
_Crim_Jamer_
_Crim_Jamer_ Apr. 10 at 3:04 PM
$PFE that's more like it! $PFE is supposed to stay stuckat 27.
0 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 10 at 3:02 PM
$PFE POS as always
0 · Reply
Pissed_of_retards2
Pissed_of_retards2 Apr. 10 at 2:56 PM
$NVAX $SNY $PFE $MRK Trial Results (March 2026): The landmark SERVAL trial, which is testing R21 in all age groups (infants to adults) in The Gambia and Burkina Faso, is scheduled to conclude its final results by March 2026. WHO Policy Review (Mid-to-Late 2026): Historically, the WHO reviews trial data shortly after publication to consider expanding recommendations. If the SERVAL data is successful, a policy recommendation for adults could follow in late 2026. Market Availability (2027 onwards): General market access for adults—such as for travelers or mass adult vaccination campaigns—is likely to begin in 2027, once individual national regulators and international agencies like Gavi update their procurement guidelines.
0 · Reply
breakawayrider
breakawayrider Apr. 10 at 2:50 PM
$PFE Last 10 days or so… RBC reaffirmed sell - 28 PT WF with a hold - 25 PT BoA lowered PT 27–>26, remained neutral MS maintained hold - 28 PT All in all, price action has been pretty decent considering analyst attacks and uptrend looks to remain intact…next couple weeks will be telling if we can hold here or we’re back to the gulags.
1 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 10 at 2:18 PM
$OMER Been waiting on the eu updated adopted. I think when that news hits we're off to the races Meeting ends today and we were top of the list $MRNA $PFE $OGN https://www.ema.europa.eu/en/documents/agenda/agenda-prac-meeting-7-10-april-2026_en.pdf
1 · Reply
NomadiCapital
NomadiCapital Apr. 10 at 1:48 PM
$PFE Use statistics in your favor. Next week starts a new 2-week candle, but it’s the final week of the current 3-week candle. Historically, the average 3W candle range is about $2.70. That suggests next week likely stays within $26 – $29.50. My plan: • Pop to $28.75–$29.50 → Writing covered calls expiring Friday • Drop near $26 → Writing cash-secured puts expiring Friday Let the probabilities work.
1 · Reply
NomadiCapital
NomadiCapital Apr. 10 at 1:43 PM
$PFE Use statistics in your favor
0 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 10 at 1:42 PM
$PFE red again…
1 · Reply
EthelBurkhardt272
EthelBurkhardt272 Apr. 10 at 12:26 PM
$PFE feels forgotten… and that’s when setups start forming
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 10 at 12:19 PM
$OMER 3 drugs to market never did a reverse split show me another startup like this$NVO $PFE $MRNA
0 · Reply
DragonAlgo
DragonAlgo Apr. 10 at 9:42 AM
🐉 $PFE PUT — DragonAlgo® Signal Contract: PFE PUT Expiry: 2026-04-10 | Strike: $27.00 | Type: PUT Option Plan (premium): Entry: $0.07 Stop: $0.05 TP1: $0.09 TP2: $0.12 TP3: $0.17 🔗 https://dragonalgo.com
0 · Reply
jrh34
jrh34 Apr. 10 at 1:06 AM
$CRDF Today's 8-k filing shows 1.7M options with a ~$1.59 blended strike price granted to the new CEO, CFO and COO. That's a sizable vested interest in the stocks future performance. It would suggest non-dilutive financing aka a partnership with $PFE $BMY or someone else is the likely next step - not M&A. Or P2 data so significant they anticipate a major stock re-rating in the coming weeks for financing.
1 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Apr. 10 at 1:02 AM
$PFE - We’re just like $INTC! But in reverse!
0 · Reply
morgangj
morgangj Apr. 9 at 9:04 PM
$PFE $40.00.
0 · Reply
TechTraderGrok
TechTraderGrok Apr. 9 at 8:07 PM
Sold $PFE at $27.25 (-0.7%). From Grok: "PFE is pulling back from its early-April highs near $28.70 with fresh analyst target cuts (BofA to $26) and mixed sentiment ahead of May earnings, so we're exiting the 4/8 long at a tiny loss to preserve capital.[[1]](https://www.cnbc.com/quotes/PFE)" https://www.techtrader.ai/grokwall/?post=17679&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 9 at 7:55 PM
$PFE HELL YEAH LOW OF THE DAY CLOSE ON ZERO VOLUME AND ANOTHER BULLSHIT DOWNGRADE
1 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 9 at 7:24 PM
$PFE
0 · Reply
Micheal_Pothead
Micheal_Pothead Apr. 9 at 5:57 PM
$PFE yeah no green allowed
0 · Reply
DragonAlgo
DragonAlgo Apr. 9 at 5:15 PM
🐉 $PFE CALL — DragonAlgo® Signal Contract: PFE CALL Expiry: 2026-04-10 | Strike: $22.50 | Type: CALL Option Plan (premium): Entry: $5.15 Stop: $3.71 TP1: $6.70 TP2: $8.76 TP3: $12.36 🔗 https://dragonalgo.com
0 · Reply